In This Article:
| WHO | WHAT | WHERE | WHEN | WHY |
| Nuwellis, Inc. | Issuance of U.S. Patent No. 12,280,007. | United States Patent and Trademark Office | April 22, 2025 | To protect a novel self-emptying fluid bag design that improves nursing workflow while maintaining system accuracy. |
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced the issuance of U.S. Patent No. 12,280,007 by the U.S. Patent and Trademark Office. The newly granted patent covers a fluid bag design that passively drains once full—reducing the need for manual intervention by clinical staff while preserving the system’s precise weight-based measurement.
This design uses a novel siphon mechanism built into the geometry of the bag, allowing it to automatically empty without disconnecting from the scale. By maintaining measurement integrity and automating a routine task, the feature offers a more seamless experience in therapy delivery.
Fluid overload is a common and serious complication in critically ill patients, and accurate, efficient ultrafiltration is essential in managing it effectively. Design enhancements like those disclosed in this patent can have a meaningful impact on both care and workflow.
“Clinicians in critical care are constantly balancing precision and efficiency,” said John Erb, Interim Chief Executive Officer of Nuwellis. “This patent reflects our commitment to supporting them with smarter design — simplifying routine tasks without compromising the accuracy their patients depend on.”
While not expected to be included in the initial release, the design may be integrated into future Aquadex SmartFlow system enhancements, including Nuwellis’ Vivian pediatric-focused CRRT device currently under development. The patent represents one of several steps the company is taking to expand its portfolio and advance continued innovation in fluid management.
The patent officially issued on April 22, 2025, and includes a 224-day extension to its standard term granted by the USPTO.
For more information, visit www.nuwellis.com.
About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter.